Preclinical antitumor activity of batracylin (NSC 320846) Jacqueline PlowmanKenneth D. PaullOmar C. Yoder Preclinical Studies Pages: 147 - 153
Anticancer activity of bisphosphonic acids in methylnitrosourea-induced mammary carcinoma of the rat — benefit of combining bisphosphonates with cytostatic agents F. WingenB. L. PoolD. Schmähl Preclinical Studies Pages: 155 - 167
Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells Maciej KawalecTomasz SkórskiJerzy Kawiak Preclinical Studies Pages: 169 - 172
Evaluation of cardiotoxicity of a new anthracycline derivative: 4′ -deoxy-4′ -iodo-doxorubicin Fabrizio VillaniMilena GalimbertiPaola Poggi Preclinical Studies Pages: 173 - 178
A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma Paul B. ChapmanJonathan E. KolitzRoland Mertelsmann Clinical Studies Pages: 179 - 188
Phase I trial of the polyelectrolyte carbetimer administered i.v. once every four weeks Michael FrommWolfgang E. BerdelJohann Rastetter Clinical Studies Pages: 189 - 194
Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer Stephen E. JonesRobert G. MennelPatty McGuffey Clinical Studies Pages: 195 - 198
Phase I — Preliminary phase II trial of iproplatin, a cisplatin analogue Frank P. PaolozziRobert GaverSandra Ginsberg Clinical Studies Pages: 199 - 206
Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study Daniele J. PerraultDiane M. LoganElizabeth A. Eisenhauer Clinical Studies Pages: 207 - 210
Phase II trial of recombinant Beta (IFN-Betaser) interferon in the treatment of metastatic breast cancer Luis BarrerasCharles L. VogelStephen G. Marcus Clinical Studies Pages: 211 - 215
Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma Paul Y. HoloyeDavid T. CarrDiane Jeffries Clinical Studies Pages: 217 - 218
A phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer P. PresgraveR. WoodsJ. Levi Clinical Studies Pages: 219 - 221
A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study Bernard L. ZidarStephanie GreenLiboria Militello Clinical Studies Pages: 223 - 226
Phase II trial of menogaril in advanced colorectal cancer Eduard E. HoldenerWim W. ten Bokkel HuininkHerbert M. Pinedo Clinical Studies Pages: 227 - 230
Cisplatin, VP-16-213 and MGBG (Methylglyoxal bis guanylhydrazone) combination chemotherapy in refractory lymphoma, a phase II study Lyubica DabichMarcia K. Liepman Clinical Studies Pages: 231 - 237
Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity David M. NanusDavid P. KelsenMario Eisenberger Clinical Studies Pages: 239 - 241
Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy Mary McCabeFrederick P. SmithPhilip S. Schein Clinical Studies Pages: 243 - 246
Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: A Southwest Oncology Group study John D. CowanStephanie GreenLaurence H. Baker Letter to the Editor Pages: 247 - 248
